BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Merck KGaA, and SpringWorks Therapeutics, Inc. (SWTX) announced they have entered into a definitive agreement for Merck KGaA to acquire SpringWorks. The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion. Merck KGaA said, upon closing, the business combination will immediately contribute to revenues and is expected to be accretive to earnings per share pre in 2027.
SpringWorks Therapeutics is a U.S. biopharmaceutical company with a systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
